Login to Your Account



Intercell Gets €62M for Starters in GSK Vaccine Patch Alliance

By Cormac Sheridan


Wednesday, December 16, 2009

No Abstract

 

BioWorld International Correspondent

Intercell AG is strengthening an already solid cash position of €139.7 million (US$203 million) by immediately adding another €62 million, thanks to a wide-ranging strategic alliance with the GSK Biologicials arm of GlaxoSmithKline plc, based on its needle-free, patch-based vaccine in development for travelers' diarrhea and its enhancement patch for pandemic flu vaccines. It also stands to gain a share of the profits from global sales of the two products.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription